new england journal of medicine tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Read the full SURPASS-CVOT trial New England Journal Of Medicine

-5.7 kg semaglutide) and improved lipid profile (triglycerides -19% to -24.8% vs

Mindful eating thus represents a scientifically grounded and effective approach to optimizing digestion and improving overall health (336)

& Solini, A

Tirzepatide (Mounjaro, Zepbound) is a once-weekly injectable medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist activity

Read next Doctor Marianne Guenot is a science reporter based in the UK who writes about health, AI, nuclear sciences, archeology, solar and planetary sciences, space exploration, and the commercial and political impact of science and tech

You want to know: how your appetite changed whether your training performance held up whether GI symptoms are settling whether your A1C, waist, or fasting glucose moved That is the kind of data that tells you whether a compound is helping or just making the scale look good for a while